Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma

• Published in: Frontiers in immunology Vol. 14; p. 1068662
• Main Authors: Yap, Daniel Ren Yi, Lim, Jing Quan, Huang, Dachuan, Ong, Choon Kiat, Chan, Jason Yongsheng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 26.01.2023
• Subjects: Biomarkers; checkpoint immunotherapy; genomics; Humans; Immunology; Immunotherapy; Killer Cells, Natural - pathology; Lymphoma, T-Cell, Peripheral - drug therapy; precision oncology; targeted therapy; Treatment Outcome; tumor microenvironment; checkpoint immunotherapy; precision oncology; targeted therapy; genomics; tumor microenvironment
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1068662

Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare subtypes of non-Hodgkin’s lymphoma that are typically associated with poor treatment outcomes. Contemporary first-line treatment strategies generally involve the use of combination chemoimmunotherapy, radiation and/or stem cell transplant. Salvage options incorporate a number of novel agents including epigenetic therapies (e.g. HDAC inhibitors, DNMT inhibitors) as well as immune checkpoint inhibitors. However, validated biomarkers to select patients for individualized precision therapy are presently lacking, resulting in high treatment failure rates, unnecessary exposure to drug toxicities, and missed treatment opportunities. Recent advances in research on the tumor and microenvironmental factors of PTCL and NKTCL, including alterations in specific molecular features and immune signatures, have improved our understanding of these diseases, though several issues continue to impede progress in clinical translation. In this Review, we summarize the progress and development of the current predictive biomarker landscape, highlight potential knowledge gaps, and discuss the implications on novel therapeutics development in PTCL and NKTCL.